Cue Biopharma said its hives candidate hit its primary endpoint in a Phase 2 study, clearing a path toward a Phase 2b/3 trial aimed at challenging Xolair. The company’s update signals clinical momentum in chronic spontaneous urticaria, where efficacy and safety in defined patient groups remain key competitive differentiators. The report frames the next step as confirmation and expansion of benefit, with later-stage design likely focused on dose optimization, responder depth, and durability. For the biotech sector, this is another example of midstage readouts driving partner expectations and future trial funding decisions in immunology.